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Highlights 
 
• Patients with HF of an ischemic etiology had the highest rate of death and/or HF hospitalization. 
• Patients with worsening HF precipitated by renal failure were associated with highest risk of death 
and/or HF hospitalization.  
• There was no interaction between HF etiologies and precipitating factors for worsening HF with 
regards to the study outcomes. 
• Treatment up-titration likely benefits patients irrespective of their etiology and/or precipitant factor. 
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Abstract 
Background 
Knowledge on the association between heart failure (HF) etiologies, precipitant causes and clinical 
outcomes may help in ascertaining patient’s risk and in selecting tailored therapeutic strategies.  
Methods 
The prognostic value of both HF etiologies and precipitants for worsening HF were analyzed using the 
index cohort of BIOSTAT-CHF. The studied HF etiologies were: a) ischemic HF; b) dilated 
cardiomyopathy; c) hypertensive HF; d) valvular HF; and e) other/unknown. The precipitating factors 
for worsening HF were: a) atrial fibrillation; b) non-adherence; c) renal failure; d) acute coronary 
syndrome; e) hypertension; and f) Infection. The primary outcome was the composite of all-cause 
death or HF hospitalization. 
Results 
Among 2,465 patients included in the study, 45% (N=1102) had ischemic HF, 23% (N=563) dilated 
cardiomyopathy, 15% (N=379) other/unknown, 10% (N=237) hypertensive and 7% (N=184) valvular 
HF. Patients with ischemic HF had the worst prognosis, whereas patients with dilated cardiomyopathy 
had the best prognosis. From the precipitating factors for worsening HF, renal failure was the one 
independently associated with worse prognosis (adjusted HR (95%CI)=1.48 (1.04-2.09), p<0.001).  
We found no interaction between HF etiologies and precipitating factors for worsening HF with regard 
to the study outcomes (p interaction>0.10 for all). Treatment up-titration benefited patients regardless 
of their underlying etiology or precipitating cause (p interaction>0.10 for all).  
Conclusions 
In BIOSTAT-CHF, patients with HF of an ischemic etiology, and those with worsening HF 
precipitated by renal failure (irrespective of the underlying HF etiology), had the highest rates of death 
and HF hospitalization, but still benefited equally from treatment up-titration.  
Keywords: Heart failure; etiology; precipitating factor; prognosis  
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Introduction 
Heart failure (HF) therapies have improved patient outcome over the last decades, however those with 
worsening symptoms and/or signs of HF still have a poor prognosis 1, 2. Both the etiology of HF and 
the factors leading to its decompensation may influence outcomes and drug response 3-7. Previous 
studies have shown that patients with HF of an ischemic etiology have worse prognosis than those 
with non-ischemic etiology 8, 9, and patients with worsening HF precipitated by infection or worsening 
renal function had worse prognosis than those with worsening HF precipitated by hypertension or 
noncompliance 7, 10, 11. Nonetheless, the prognostic assessment of the HF etiologies and the worsening 
HF precipitating factors as well as their interaction and response to treatment, is yet to be determined. 
The systems BIOlogy study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) allows 
the study of the associations between the HF etiologies, precipitants for worsening HF, treatment up-
titration and clinical outcomes.  
The main aims of the present study were; 1) to describe the clinical characteristics of the 
patients with regard to their HF etiologies and worsening HF precipitants; 2) to study the association 
between HF etiologies and worsening HF precipitants with outcomes; 3) to assess whether the 
prognostic implications of the precipitating factors may be modified by the HF etiologies (and vice-
versa); 4) to assess whether the potential benefits of treatment up-titration are influenced by the HF 
etiology and/or precipitant.  
 
Methods 
Patient Population 
The BIOSTAT-CHF was an international study and its main features have been previously described 
12, 13. Included patients were ≥18 years of age with symptoms of new onset or worsening HF, 
confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or a B-type natriuretic peptide 
or N-terminal pro–B-type natriuretic peptide (NT-proBNP) plasma levels>400pg/ml or>2,000 pg/ml, 
respectively. Patients needed to be treated with either oral or intravenous furosemide ≥40 mg/day or 
equivalent at the time of inclusion. From the 2,516 patients, we selected the 2,465 patients who had 
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specific information on the HF etiologies (Figure 1). Patients were receiving <50% of the target doses 
of at least one of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 
(ACEi/ARBs) and beta-blockers at the time of inclusion. The first 3 months of treatment were 
considered to be a treatment optimization phase. During the optimization phase, initiation or up-
titration of ACEi/ARB and/or beta-blocker was done according to the routine clinical practice of the 
treating physicians, who were encouraged to follow the European Society of Cardiology guideline 14. 
Patients reaching at least 50% of the recommended dose of ACEi/ARB and/or beta-blocker at the 3-
month visit were considered successfully up-titrated. 
BIOSTAT-CHF was conducted in concordance with the declaration of Helsinki, national 
ethics and legal requirements, as well as relevant EU legislation. The study was approved by national 
and local ethics committees and all patients recruited in BIOSTAT-CHF were given written informed 
consent to participate in the study.  
 
Precipitating Factors and Heart Failure Etiology 
HF etiology was characterized according to the specified cases in the case report form (CRF) in 
categories of ischemic etiology, dilated cardiomyopathy, hypertensive, valvular etiology, and 
other/unknown according to the treating clinical physicians (Supplementary table 1). 
In the BIOSTAT-CHF protocol/CRF, there were six different classifications of worsening HF 
precipitating factors from which clinicians could choose (“tick box”): acute coronary syndrome 
(ACS), atrial fibrillation (AF), hypertension, renal failure, infection and non-adherence (diet, 
medications or iatrogenic). These factors were collected in the CRF, as per investigator clinical 
judgement according to the ESC guidelines 14 (Supplementary table 1). More than 1 factor could be 
selected (whenever applicable). These factors were identified by the local investigators for each 
patient. The definitions provided by the above referenced guidelines were encouraged, where: ACS, 
would require elevation of troponin I above the 95th percentile and dynamic electrocardiographic 
alterations suggestive of acute myocardial ischemia 15; AF, presence of AF on the electrocardiogram; 
hypertension, office systolic blood pressure (SBP)>140 mmHg; renal failure, creatinine >1.5 mg/dl 
and or deterioration (>20% eGFR drop)of renal function compared with the last available 
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measurement; and infection, with elevated inflammatory parameters, e.g., leucocyte, c-reactive peptide 
or procalcitonin. 
 
Statistical Analysis 
Categorical variables are described as frequencies (percentages) and continuous variables are 
described as means ± standard deviation or median [25th and 75th percentiles] depending on their 
distribution. Comparisons of demographic, clinical and biological parameters among HF etiologies 
were conducted using χ² tests for categorical variables and Kruskal-Wallis test or Mann-Whitney test 
for continuous variables.  
The primary outcome was the composite of all-cause mortality or HF hospitalization. Time-
to-event comparisons were analyzed using log rank test and Cox proportional hazards models. 
Survival probabilities were estimated using the Kaplan-Meier method and plotted as survival curves 
with HF etiologies and worsening HF precipitants at 400 and 60 days, respectively, due to violation of 
proportional hazards after these time-points (the Kaplan-Meier curves during overall term follow-up 
are shown in the Supplementary figure 1).  
Cox proportional-hazards models for HF etiologies and worsening HF precipitating factors 
were then used to obtain unadjusted and covariate adjusted hazard ratios (HRs) (with dilated 
cardiomyopathy and non-adherence as the reference groups, respectively). Multivariable models were 
adjusted for BIOSTAT-CHF risk model 16. The risk model for the composite outcome included age, 
HF hospitalization in the year before inclusion, presence of edema, NT-proBNP, SBP, hemoglobin, 
high-density lipoprotein levels, serum sodium concentration, and absence of beta-blocker. The risk 
model for all-cause mortality or cardiovascular mortality included age, higher blood urea nitrogen and 
NT-proBNP, lower hemoglobin and failure to prescribe a beta-blocker 16. Furthermore, we performed 
multivariable analyses after adjusting for ischemic etiology/renal failure in addition to aforementioned 
covariates. An interaction test was performed to determine whether the effect of respective precipitants 
would be influenced by the HF etiology, and whether the response to treatment could be influenced by 
either HF etiology or precipitant.  
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All analyzes were performed using R version 3.4.0. (R Development Core Team, Vienna, 
Austria). P-value<0.05 was considered statistically significant. 
 
Results 
Patient Characteristics by Heart Failure Etiology 
 Of the 2,465 patients included in this study, the mean age was 68.4±12.0 years old, 73.2% was male, 
the mean LVEF was 31.0±10.5%, and 67.1% of patients were hospitalized. With regard to the HF 
etiology, 45% (N=1102) had ischemic HF, 23% (N=563) dilated cardiomyopathy, 15% (N=379) 
other/unknown, 10% (N=237) hypertensive and 7% (N=184) valvular HF (Table 1). Compared to 
patients with non-ischemic HF, patients with ischemic HF were older (mean age 70 vs 67 years), more 
often male (80 vs 68%) and had more cardiovascular comorbidities and poorer renal function (all 
P<0.001). Amongst all etiologies, patients with dilated cardiomyopathy were the youngest, had fewest 
comorbidities, best renal function and highest prescription rates of ACEi/ARB and mineralocorticoid 
receptor antagonist (MRA) prescriptions.  
 
Distribution of Precipitating Factors According to Heart Failure Etiology 
Patients with ischemic HF were more often precipitated by ACS (Table 2). Patients with hypertensive 
HF were mainly precipitated by both hypertensive crisis and AF, and the latter was also a major 
precipitant in patients with valvular HF and dilated cardiomyopathy. The patient characteristics 
according to the respective precipitating factors are depicted in the Supplementary table 2.  
 
Association of Heart Failure Etiologies with Outcomes 
The primary outcome occurred in 46.7%, 45.6%, 42.2%, 35.9% and 29.3% of patients with valvular, 
ischemic, hypertensive HF, other/unknown etiology and dilated cardiomyopathy, respectively. 
Kaplan-Meier curves showed worse prognoses for valvular and ischemic HF (Supplementary figure 
2). Ischemic HF remained the worst prognosis in the survival analyses adjusted for BIOSTAT-CHF 
risk model (Figure 2); with a corresponding adjusted HR (95%CI) =1.34 (1.12-1.60), p<0.001 (Table 
3). Patients with ischemic HF retained the worst prognosis after adjusting for aforementioned risk 
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model plus renal function; adjusted HR (95%CI)=1.34 (1.12–1.60), p=0.001, and there was no 
interaction between ischemic HF and renal failure as a precipitant (p=0.30). Similar association 
between HF etiologies and primary outcome was observed in patients with a LVEF of ≤40% 
(Supplementary table 4). Furthermore, patients with ischemic HF tended to be associated with higher 
incidence of cardiovascular mortality (p=0.08), but no specific HF etiology was associated with all-
cause mortality (all P-value>0.1). As a sensitivity analysis, the associations of HF etiologies with the 
primary outcome in ambulatory and hospitalized patients are shown in the Supplementary table 3. 
 
Association of Worsening HF Precipitating Factors with Outcomes 
The primary outcome occurred in 68.0%, 45.3%, 40.3%, 39.1%, 36.8% and 36.3% of the patients 
precipitated by renal failure, infection, hypertension, AF, ACS and non-adherence, respectively. After 
adjusting for BIOSTAT-CHF risk model and ischemic etiology, renal failure was associated with 
higher incidence of the primary outcome; adjusted HR (95%CI)=1.49 (1.05-2.10), p=0.003 (Table 4). 
Renal failure also tended to be associated with higher risk of all-cause mortality; adjusted HR 
(95%CI)=1.44 (0.96-2.15), p=0.08. With regard to the primary outcome, there was no significant 
interaction between HF etiology and the worsening HF precipitants (p=0.95).   
 
Association and Interaction with Treatment Up-Titration 
Patients with HF of hypertensive etiology had more often successful treatment up-titration, whereas 
patients with valvular HF were less often up-titrated (Table 1).  
Interaction tests for the primary outcome did not show treatment up-titration heterogeneity 
with regard to HF etiologies and/or precipitant factors (all P-value>0.10) (Table 5). 
 
Discussion 
In ambulant and hospitalized patients with worsening HF, we assessed the clinical characteristics and 
outcome of different etiologies and precipitating factors. We found that patients with ischemic HF and 
worsening HF precipitated by renal failure had the worst prognosis. These findings suggest that both 
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the HF etiology and the precipitating factors provide relevant and independent prognostic information, 
and that treatment up-titration was not influenced by HF etiologies and precipitating factors.  
Heart Failure Etiologies 
Our results align with previous reports suggesting that the most common HF etiology was ischemia 6, 
17. Patients with ischemic HF were older, had more cardiovascular risk factors, comorbidities and were 
associated with higher risk at cardiovascular mortality and morbidity 8, 9, 18, 19. In particular, patients 
with a LVEF ≤40% of an ischemic etiology had worse prognosis, which is consistent with previous 
studies 4, 18.  
Among patients with non-ischemic HF, valvular HF has also been associated with worse 
prognosis 4, as also confirmed in the present study. Progressive valvular degeneration may increase the 
volume and/or pressure overload associated with an increased rate of HF hospitalization and death 20, 
21. Indeed, in our study, patients with a valvular HF had worse clinical status, illustrated by high 
proportion of anemia and impaired renal function, which may contribute to worse outcomes. In 
contrast, dilated cardiomyopathy was associated with better outcomes. Favorable trends in optimal 
treatments and low prevalence of comorbidities have been recently documented, potentially leading to 
lower rates of adverse outcomes 22, 23. In the present analysis, patients with a dilated cardiomyopathy 
were the youngest, had good renal function, and higher baseline MRA prescriptions, which may be 
associated with their improved prognosis among HF etiologies 24-26.  
 Patients with HF of a hypertensive etiology might have been more often successfully up-
titrated, while those with HF of a valvular etiology were less likely to be up-titrated. However, 
treatment up-titration, when it occurred, likely benefited patients irrespective of their HF etiology 27. 
Precipitating Factors 
With regard to the worsening HF precipitating factors, our results were also consistent with the 
previously published studies. Patients with HF precipitated by renal failure were elderly, had more 
frequent prior HF admission, more comorbidities, more severe congestion and worse prognosis 10, 28-31. 
Renal failure as a precipitant may be determined by clinical deterioration and by therapeutic approach 
such as diuresis and renin angiotensin aldosterone system inhibitors 3. In the present analysis, patients 
with renal failure were not likely to receive ACEi/ARB, MRA and diuretics, suggesting that renal 
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failure in this setting may not be considered to be a subsequent deterioration. Moreover, our results 
show that the occurrence of renal failure may discourage physicians from up-titrating ACEi/ARB and 
be associated with worse prognosis irrespective of treatment up-titration. Therefore, our observations 
may further increase the clinician’s awareness for patients with worsening HF precipitated by renal 
failure, who might need closer surveillance. 
Patients with HF precipitated by non-adherence were younger, had lower LVEF and more 
frequent prior HF admissions 5, 11, whereas patients with hypertension had less comorbidities and less 
severe congestion 5, 32. Both of the precipitants, non-adherence (used as referent variable in our 
analyses) and hypertension, have been associated with more favorable outcomes 5. Conversely, our 
results did not show worse prognosis of either ACS or infection as a precipitant. ACS and infection 
have been reported to be associated with worse short-term outcomes 5, prognostic implication of these 
precipitants may vary thus with term follow-up. In addition, anemia is also presumably considered as a 
precipitant in clinical practice. In the present analysis, however, <1.0 % of patients (N=21) were 
precipitated by anemia, which is concordant with previous reports 5, 10, 28, 29.  
Interplay between Heart Failure Etiologies and Precipitating Factors 
ACS was a frequent precipitant in patients with ischemic HF, whereas hypertension was a frequent 
precipitant in patients with hypertensive HF, both of which were consistent with previous literature 32, 
33.  In contrast, patients with valvular HF were more likely to be precipitated by AF and renal failure. 
The disappearance of atrial contraction in AF or extensive fluid volume overload in renal failure, may 
contribute to be decompensated phase in patients with valvular HF 20, 21, 34, 35.  
To the best of our knowledge, this is the first report to study and relate the HF etiologies to the 
worsening HF precipitating factors. We found no statistical interaction between the HF etiology and 
the worsening HF precipitants with regard to the study outcomes, suggesting that both entities may 
have independent prognostic value. Our observations may help potentially clinicians in better 
identifying the worsening HF precipitants in the light of the patient’s history and also in identifying 
those patients at higher risk of subsequent events. 
Limitations 
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Our study has several limitations. This is a post-hoc analysis of the BIOSTAT-CHF, hence the 
limitations inherent to observational data are present herein, as a consequence we cannot infer 
causality nor exclude residual confounders. By design, BIOSTAT-CHF enrolled patients who had no 
optimal guideline medical therapy or no anticipated need for cardiac transplantation or ventricular 
assist device. Although, this condition is frequent, results may not be generalizable to these patients. 
The HF etiologies and precipitants were ascertained by the treating physicians in their routine clinical 
practice. The detailed clinical information of HF etiologies such as valvular HF and dilated 
cardiomyopathy were not available, while the number of precipitants might have been underreported; 
for example, dietary factors such as excessive salt intake and concomitant drugs such as steroidal and 
non-steroidal inflammatory drugs. We selected patients with single precipitant in survival analysis 
regarding respective precipitants. Therefore, the number of each individual precipitant was small, 
potentially having limited power of the associations. Our results, however, were consistent with 
previous reports, reinforcing the external validation of our findings. After adjustment, patients with 
ischemic HF was not associated with all-cause mortality (but tended to be associated with 
cardiovascular mortality), suggesting that the associations with all-cause death alone, might have been 
diluted by death of non-cardiovascular causes. In BIOSTAT-CHF, the number of patients with 
preserved LVEF was small, leading to difficulty in survival analysis across LVEF strata. Finally, 
interaction analyses may lack statistical power, however, these analyses are exploratory and only if 
some strong between-group difference was present, that interaction could be observed. 
 
Conclusions 
Both etiology and precipitating factors for worsening HF may provide independent prognostic 
information. Patients with HF of an ischemic etiology, and those with worsening HF precipitated by 
renal failure had the worst clinical prognosis. Treatment up-titration likely benefits patients 
irrespective of their etiology or precipitant factor. These findings may help in better identifying 
patient’s risk based both on their HF etiology and the factor that led to the visit, and should encourage 
the up-titration of life-saving therapies irrespective of the HF etiology and/or a precipitant.  
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Table 1. Patient Characteristic according to the Heart Failure Etiologies 
Values are Mean ± SD, n (%) or median (25th to 75th percentile) 
BMI, body mass index; PAD, peripheral artery disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; NYHA, 
New York Heart Association; ECG, electrocardiogram; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; ACEi, 
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; eGFR, 
estimated glomerular filtration rate; NT-proBNP, N-terminal prohormone brain natriuretic peptide. 
 
Table 2. Prevalence of Precipitating Factors according to the Heart Failure Etiologies 
 
Table 3. Cox Proportional Hazard Models of the Heart Failure Etiologies for the Clinical Outcomes 
HR, hazard ratio; CI, confidence interval; HF, heart failure. 
 
Table 4. Cox Proportional Hazard Models of Precipitating Factors for the Clinical Outcomes 
HR, hazard ratio; CI, confidence interval; HF, heart failure. 
 
Table 5.  Cox Proportional Hazard Models for the Primary Outcome according to Successful Up-ti-
tration of ≥50% of Guideline-Recommended Target Doses 
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Table 1. Patient Characteristic according to the Heart Failure Etiologies 
  Global (N=2465) 
Ischemic HF  
(N=1102) Non-ischemic HF 
P-value between 
ischemic vs  
non-ischemic  
P-value among 
all etiologies 
  
    
Overall 
(N=1363) 
Hypertensive HF 
(N=237) 
Valvular HF 
(N=184) 
Dilated 
Cardiomyopathy 
(N=563) 
Other/Unknown 
(N=379) 
   
 
    
Age, yrs 68.4 ± 12.0 70.0 ± 10.6 67.1 ± 12.8 72.9 ± 10.3 71.7 ± 11.5 62.3 ± 12.7 68.1 ± 12.5 <0.001 <0.001 
Male, N (%) 1805 (73.2 %) 883 (80.1 %) 922 (67.6 %) 135 (57.0 %) 103 (56.0 %) 425 (75.5 %) 259 (68.3 %) <0.001 <0.001 
BMI, kg/m² 27.9 ± 5.5 28.1 ± 5.3 27.8 ± 5.6 28.4 ± 5.6 26.5 ± 4.9 27.6 ± 5.3 28.2 ± 6.3 0.09 0.003 
Medical history          
  Hypertension, N (%) 1539 (62.4 %) 767 (69.6 %) 772 (56.6 %) 230 (97.0 %) 101 (54.9 %) 251 (44.6 %) 190 (50.1 %) <0.001 <0.001 
  Diabetes mellitus, N (%) 798 (32.4 %) 447 (40.6 %) 351 (25.8 %) 87 (36.7 %) 32 (17.4 %) 136 (24.2 %) 96 (25.3 %) <0.001 <0.001 
  Myocardial infarction, N (%) 940 (38.1 %) 838 (76.0 %) 102 (7.5 %) 19 (8.0 %) 12 (6.5 %) 25 (4.4 %) 46 (12.1 %) <0.001 <0.001 
  Stroke, N (%) 231 (9.4 %) 135 (12.3 %) 96 (7.0 %) 20 (8.4 %) 17 (9.2 %) 27 (4.8 %) 32 (8.4 %) <0.001 <0.001 
  PAD, N (%) 267 (10.8 %) 169 (15.3 %) 98 (7.2 %) 26 (11.0 %) 16 (8.7 %) 26 (4.6 %) 30 (7.9 %) <0.001 <0.001 
  COPD, N (%) 423 (17.2 %) 204 (18.5 %) 219 (16.1 %) 38 (16.0 %) 29 (15.8 %) 88 (15.6 %) 64 (16.9 %) 0.11 0.59 
  Valvular surgery, N (%) 176 (7.1 %) 73 (6.6 %) 103 (7.6 %) 4 (1.7 %) 69 (37.5 %) 16 (2.8 %) 14 (3.7 %) 0.42 <0.001 
Prior HF admission, N (%) 780 (31.6 %) 383 (34.8 %) 397 (29.1 %) 71 (30.0 %) 56 (30.4 %) 181 (32.1 %) 89 (23.5 %) 0.003 0.002 
Clinical profile          
  NYHA class ≥III, N (%) 1491 (62.2 %) 680 (63.1 %) 811 (61.4 %) 145 (63.3 %) 127 (71.3 %) 321 (58.5 %) 218 (59.9 %) 0.41 0.03 
  Rales, N (%) 240 (19.0 %) 107 (18.8 %) 133 (19.1 %) 25 (18.4 %) 18 (16.2 %) 34 (13.4 %) 56 (28.9 %) 0.88 0.001 
  Juglar venous pressure, N (%) 544 (31.5 %) 249 (31.4 %) 295 (31.6 %) 43 (29.7 %) 54 (41.2 %) 112 (28.5 %) 86 (32.6 %) 0.92 0.10 
  Leg edema, N (%) 1230 (59.6 %) 511 (55.4 %) 719 (63.1 %) 136 (69.4 %) 120 (76.4 %) 254 (53.8 %) 209 (66.3 %) <0.001 <0.001 
  Systolic blood pressure, mmHg 124.8 ± 21.9 124.2 ± 20.9 125.3 ± 22.6 140.6 ± 26.8 123.0 ± 21.2 121.0 ± 19.2 123.4 ± 21.3 0.39 <0.001 
  Heart rate, bpm 79.9 ± 19.5 75.9 ± 16.1 83.1 ± 21.3 84.2 ± 20.9 86.1 ± 22.1 81.3 ± 19.8 83.8 ± 23.0 <0.001 <0.001 
Hospitalized patients, N (%) 1655 (67.1 %) 706 (64.0 %) 949 (69.6 %) 156 (65.8 %) 148 (80.4 %) 366 (65.0 %) 279 (73.6 %) 0.003 <0.001 
Echocardiogram          
  LVEF, % 31.0 ± 10.5 30.4 ± 9.0 31.4 ± 11.6 36.8 ± 11.6 37.3 ± 14.7 26.7 ± 7.8 32.5 ± 11.8 0.85 <0.001 
  LVEF ≤40%, N (%) 1973 (89.7 %) 915 (93.8 %) 1058 (86.4 %) 170 (77.3 %) 116 (69.0 %) 517 (98.3 %) 255 (82.3 %) <0.001 <0.001 
  MR ≥moderate, N (%) 1103 (47.1 %) 483 (46.4 %) 620 (47.7 %) 98 (43.0 %) 96 (54.5 %) 272 (50.8 %) 154 (42.8 %) 0.51 0.02 
Medication at baseline          
  ACEi or ARB, N (%) 1783 (72.3 %) 773 (70.1 %) 1010 (74.1 %) 168 (70.9 %) 123 (66.8 %) 445 (79.0 %) 274 (72.3 %) 0.03 0.001 
  Beta-blocker, N (%) 2059 (83.5 %) 964 (87.5 %) 1095 (80.3 %) 177 (74.7 %) 136 (73.9 %) 477 (84.7 %) 305 (80.5 %) <0.001 <0.001 
  MRA, N (%) 1312 (53.2 %) 601 (54.5 %) 711 (52.2 %) 98 (41.4 %) 79 (42.9 %) 346 (61.5 %) 188 (49.6 %) 0.24 <0.001 
  Loop diuretics, N (%) 2454 (99.6 %) 1101 (99.9 %) 1353 (99.3 %) 234 (98.7 %) 184 (100.0 %) 558 (99.1 %) 377 (99.5 %) 0.04 0.04 
  Digoxin, N (%) 481 (19.5 %) 150 (13.6 %) 331 (24.3 %) 46 (19.4 %) 48 (26.1 %) 145 (25.8 %) 92 (24.3 %) <0.001 <0.001 
Medication at 3 months          
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  ACEi/ARB ≥50% target dose 1286 (52.2 %) 572 (51.9 %)  714 (52.4 %) 154 (65.0 %) 70 (38.0 %) 297 (52.8 %) 193 (50.9 %) 0.81 <0.001 
  % ACEi/ARB target dose 50.0 (25.0 - 66.7) 
50.0 
(16.7 - 62.5) 
50.0 
(25.0 – 75.0) 
50.0 
(25.0 - 100.0) 
25.0 
(12.5 - 50.0) 
50.0 
(25.0 - 75.0) 
50.0 
(25.0 - 62.5) 0.08 <0.001 
  Beta-blocker ≥50% target dose 879 (35.7 %) 404 (36.7 %) 475 (34.8 %) 89 (37.6 %) 64 (34.8 %) 185 (32.9 %) 137 (36.1 %) 0.35 0.58 
  % beta-blocker target dose 25.0 (12.5 - 50.0) 
25.0 
(12.5 - 50.0) 
25.0 
(12.5 – 50.0) 
25.0 
(12.5 - 50.0) 
25.0 
(8.3 - 50.0) 
25.0 
(12.5 - 50.0) 
25.0 
(12.5 - 50.0) 0.62 0.36 
Laboratory          
  Hemoglobin, g/dl 13.2 ± 1.9 13.0 ± 1.9 13.3 ± 1.9 13.0 ± 1.8 12.8 ± 1.9 13.6 ± 1.8 13.4 ± 1.9 0.002 <0.001 
  Blood urea nitrogen, mg/dl 41.8 ± 32.6 44.8 ± 34.7 39.3 ± 30.6 37.1 ± 26.3 43.6 ± 36.4 40.1 ± 30.5 37.4 ± 29.7 <0.001 <0.001 
  eGFR, mL/min/1.73m² 62.0 ± 24.3 58.9 ± 23.2 64.5 ± 24.8 61.2 ± 24.1 58.6 ± 22.8 68.5 ± 25.7 63.9 ± 23.9 <0.001 <0.001 
  Sodium, mmol/l 139.1 ± 4.0 139.0 ± 3.9 139.3 ± 4.0 139.8 ± 4.3 139.0 ± 3.7 139.1 ± 4.0 139.3 ± 4.1 0.044 0.02 
  Potassium, mmol/l 4.3 ± 0.6 4.3 ± 0.6 4.2 ± 0.6 4.2 ± 0.6 4.2 ± 0.6 4.3 ± 0.6 4.2 ± 0.5 0.02 0.07 
  NT-proBNP, pg/ml 4280 (2359-8475) 
3988 
(2288-8220) 
4341 
(2400-8576) 
3808 
(2366-7539) 
4883 
(2621-8282) 
4339 
(1938-9019) 
4443 
(2604-8538) 0.61 0.51 
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Table 2. Prevalence of Precipitating Factors according to the Heart Failure Etiologies 
 Ischemic HF 
(N=1102) 
Hypertensive HF 
(N=237) 
Valvular HF 
(N=184) 
Dilated 
Cardiomyopathy 
(N=563) 
Other/Unknown 
(N=379) P-value 
Precipitating factor       
  Acute coronary syndrome, N (%) 94 (8.6 %) 4 (1.7 %) 2 (1.1 %) 5 (0.9 %) 16 (4.2 %) <0.001 
  Atrial fibrillation, N (%) 199 (18.1 %) 72 (30.5 %) 71 (38.8 %) 97 (17.3 %) 138 (36.5 %) <0.001 
  Hypertension, N (%) 43 (3.9 %) 51 (21.5 %) 9 (4.9 %) 12 (2.1 %) 19 (5.0 %) <0.001 
  Renal failure, N (%) 136 (12.4 %) 26 (11.0 %) 28 (15.2 %) 36 (6.4 %) 42 (11.1 %) 0.001 
  Infection, N (%) 59 (5.4 %) 13 (5.5 %) 10 (5.6 %) 20 (3.6 %) 26 (6.9 %) 0.25 
  Non-adherence, N (%) 160 (14.5 %) 25 (10.5 %) 20 (10.9 %) 86 (15.3 %) 49 (12.9 %) 0.27 
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Table 3. Cox Proportional Hazard Models of the Heart Failure Etiologies for the Clinical Outcomes 
Composite outcome 
Unadjusted Adjusted for BIOSTAT-CHF risk model 
Adjusted for BIOSTAT-CHF 
risk model plus renal failure 
P-value for 
interaction with 
renal failure HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
  Dilated cardiomyopathy (reference)  (reference)  (reference)  
0.30 
  Ischemic HF 1.76 (1.48 - 2.10) <0.001 1.34 (1.12 - 1.60) 0.001 1.34 (1.12 – 1.60) 0.001 
  Hypertensive HF 1.49 (1.16 - 1.91) 0.002 1.27 (0.99 - 1.62) 0.06 1.26 (0.98 – 1.62) 0.07 
  Valvular HF 1.85 (1.43 - 2.40) <0.001 1.21 (0.93 - 1.57) 0.16 1.21 (0.93 – 1.57) 0.16 
  Other/Unknown 1.32 (1.05 - 1.66) 0.02 1.17 (0.93 - 1.46) 0.19 1.16 (0.92 – 1.46) 0.21 
All-cause death 
Unadjusted Adjusted for BIOSTAT-CHF risk model 
Adjusted for BIOSTAT-CHF 
risk model plus renal failure 
P-value for 
interaction with 
renal failure HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
  Dilated cardiomyopathy (reference)  (reference)  (reference)  
0.46 
  Ischemic HF 1.72 (1.38 - 2.14) <0.001 1.05 (0.84 - 1.32) 0.66 1.06 (0.85 – 1.33) 0.62 
  Hypertensive HF 1.43 (1.04 - 1.95) 0.03 1.26 (0.92 - 1.73) 0.15 1.26 (0.92 – 1.73) 0.14 
  Valvular HF 1.58 (1.13 - 2.21) 0.01 1.12 (0.80 - 1.56) 0.52 1.12 (0.80 – 1.56) 0.54 
  Other/Unknown 1.34 (1.01 - 1.78) 0.04 1.15 (0.87 - 1.53) 0.32 1.15 (0.87 – 1.52) 0.33 
Cardiovascular death 
Unadjusted Adjusted for BIOSTAT-CHF risk model 
Adjusted for BIOSTAT-CHF 
risk model plus renal failure 
P-value for 
interaction with 
renal failure HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
  Dilated cardiomyopathy (reference)  (reference)  (reference)  
0.55 
  Ischemic HF 1.76 (1.35 – 2.29) <0.001 1.27 (0.97 – 1.66) 0.08 1.27 (0.97 – 1.65) 0.08 
  Hypertensive HF 1.29 (0.87 – 1.91) 0.21 1.08 (0.73 – 1.61) 0.69 1.08 (0.73 – 1.60) 0.70 
  Valvular HF 1.47 (0.97 – 2.22) 0.07 0.92 (0.60 – 1.39) 0.68 0.91 (0.60 – 1.39) 0.67 
  Other/Unknown 1.24 (0.87 – 1.75) 0.23 1.06 (0.75 – 1.50) 0.74 1.05 (0.74 – 1.49) 0.77 
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Table 4. Cox Proportional Hazard Models of Precipitating Factors for the Clinical Outcomes  
Composite outcome 
Unadjusted Adjusted for BIOSTAT-CHF risk model 
Adjusted for BIOSTAT-CHF 
risk model plus Ischemic etiology P-value for 
interaction 
with HF etiologies HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Non-adherence (reference)  (reference)  (reference)  
0.95 
Acute coronary syndrome 1.08 (0.69 - 1.71) 0.74 1.18 (0.75 - 1.87) 0.48 1.10 (0.69 - 1.75) 0.68 
Atrial fibrillation 1.10 (0.82 - 1.46) 0.54 1.01 (0.76 - 1.35) 0.95 1.04 (0.78 - 1.39) 0.78 
Hypertension 1.03 (0.66 - 1.61) 0.90 1.37 (0.88 - 2.15) 0.17 1.39 (0.89 - 2.18) 0.15 
Renal failure 2.61 (1.87 - 3.65) <0.001 1.48 (1.04 - 2.09) 0.03 1.49 (1.05 - 2.10) 0.03 
Infection 1.31 (0.85 - 2.01) 0.23 0.97 (0.62 - 1.49) 0.87 0.97 (0.63 - 1.50) 0.88 
All-cause death 
Unadjusted Adjusted for BIOSTAT-CHF risk model 
Adjusted for BIOSTAT-CHF 
risk model plus Ischemic etiology P-value for 
interaction 
with HF etiologies HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Non-adherence (reference)  (reference)  (reference)  
0.67 
Acute coronary syndrome 1.18 (0.69 - 2.01) 0.54 1.22 (0.71 - 2.07) 0.47 1.24 (0.72 - 2.12) 0.44 
Atrial fibrillation 1.06 (0.75 - 1.51) 0.73 1.04 (0.73 - 1.47) 0.85 1.03 (0.72 - 1.46) 0.89 
Hypertension 0.54 (0.27 - 1.07) 0.08 0.78 (0.39 - 1.55) 0.48 0.78 (0.39 - 1.55) 0.47 
Renal failure 2.83 (1.92 - 4.17) <0.001 1.44 (0.97 - 2.16) 0.07 1.44 (0.96 - 2.15) 0.08 
Infection 1.45 (0.88 - 2.40) 0.15 0.99 (0.59 - 1.64) 0.95 0.99 (0.59 - 1.64) 0.95 
Cardiovascular death 
Unadjusted Adjusted for BIOSTAT-CHF risk model 
Adjusted for BIOSTAT-CHF 
risk model plus Ischemic etiology P-value for 
interaction 
with HF etiologies HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Non-adherence (reference)  (reference)  (reference)  
0.73 
Acute coronary syndrome 1.40 (0.76 – 2.58) 0.29 1.57 (0.85 – 2.91) 0.15 1.48 (0.79 – 2.77) 0.22 
Atrial fibrillation 1.17 (0.77 – 1.78) 0.47 1.04 (0.68 – 1.58) 0.86 1.07 (0.70 – 1.63) 0.76 
Hypertension 0.48 (0.20 – 1.16) 0.10 0.71 (0.30 – 1.72) 0.45 0.72 (0.30 – 1.74) 0.47 
Renal failure 2.95 (1.84 – 4.72) <0.001 1.47 (0.90 – 2.40) 0.12 1.49 (0.92 – 2.43) 0.11 
Infection 1.38 (0.74 – 2.59) 0.31 0.97 (0.51 – 1.82) 0.92 0.97 (0.52 – 1.82) 0.92 
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Table 5.  Cox Proportional Hazard Models for the Primary Outcome according to Successful Up-titration of ≥50% of Guideline-Recommended Target 
Doses 
  Ischemic vs Non-ischemic HF Renal failure vs Other precipitants 
  Adjusted HR (95% CI) P-value for interaction Adjusted HR (95% CI) 
P-value for 
interaction 
Overall  1.19 (1.05 - 1.34)  1.36 (0.98 - 1.89)  
ACEi/ARB ≥50% of target dose 
Unsuccessful 1.30 (1.09 - 1.56) 
0.59 
1.51 (1.01 - 2.24) 
0.62 
Successful 1.16 (0.94 - 1.42) 1.05 (0.58 - 1.88) 
BB ≥50% of target dose 
Unsuccessful 1.22 (1.03 - 1.44) 
0.69 
1.19 (0.79 - 1.81) 
0.19 
Successful 1.27 (1.01 - 1.61) 1.94 (1.09 - 3.44) 
ACEi/ARB or BB ≥50% of target dose 
Unsuccessful 1.30 (1.05 - 1.61) 
0.72 
1.23 (0.75 - 2.02) 
0.47 
Successful 1.20 (1.01 - 1.43) 1.46 (0.93 - 2.29) 
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Figure 1. Flowchart of Patients from the BIOSTAT-CHF 
 
Figure 2. BIOSTAT-CHF risk model-adjusted Survival Curves for the Primary Outcome according to 
the Heart Failure Etiologies and Precipitating Factors 
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Figure 1. Flowchart of Patients from the BIOSTAT-CHF 
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Figure 2. BIOSTAT-CHF risk model-adjusted Survival Curves for the Primary Outcome according to the Heart Failure Etiologies and 
Precipitating Factors 
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Supplementary table 1. Heart Failure Etiologies and Precipitating Factors in the Proto-
col of BIOSTAT-CHF 
 
Supplementary table 2. Patients Characteristics according to Precipitating Factors 
Values are Mean ± SD, n (%) or median (25th to 75th percentile) 
ACS, acute coronary syndrome; PAD, peripheral artery disease; COPD, chronic obstructive pulmonary disease; 
HF, heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; MR, mitral re-
gurgitation; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineral-
ocorticoid receptor antagonist; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal prohormone 
brain natriuretic peptide. 
 
Supplementary table 3. Cox Proportional Hazard Models of the Heart Failure Etiologies 
for the Primary Outcome in Ambulant and Hospitalized Patients 
HR, hazard ratio; CI, confidence interval; HF, heart failure.  
Cox hazard model for the composite of all-cause mortality or HF hospitalization was adjusted for BIOSTAT-
CHF risk model. 
 
Supplementary table 4. Cox Proportional Hazard Models of the Heart Failure Etiologies 
for the Primary Outcome in Patients with Reduced Ejection Fraction 
HR, hazard ratio; CI, confidence interval; HF, heart failure.  
Cox hazard model for the composite of all-cause mortality or HF hospitalization was adjusted for BIOSTAT-
CHF risk model. 
 
Supplementary figure 1. Unadjusted Survival Curves for the Primary Outcome 
according to the Heart Failure Etiologies and Precipitating Factors (Overall Term 
Follow-up) 
 
Supplementary figure 2. Unadjusted Survival Curves for the Primary Outcome 
according to the Heart Failure Etiologies and Precipitating Factors 
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Supplementary table 1. Heart Failure Etiologies and Precipitating Factors in the Protocol of BIOSTAT-CHF 
5 MEDICAL HISTORY: HEART FAILURE  
Etiology assessed No 0   Yes 1 
Ischemic heart disease  
Hypertension  
Cardiomyopathy  
Valvular disease  
Unknown etiology  
Other  
Primary 1 Contributory 2 Not Present 3 Unknown 4  
Primary 1 Contributory 2 Not Present 3 Unknown 4  
Primary 1 Contributory 2 Not Present 3 Unknown 4  
Primary 1 Contributory 2 Not Present 3 Unknown 4  
Primary 1 Contributory 2 Not Present 3 Unknown 4  
Primary 1 Contributory 2 Not Present 3 Unknown 4  
 
7 FAMILY HISTORY 
 
7.7 Cause of the Heart Failure is a dilated cardiomyopathy?  
 
 
No 0 Yes 1  
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10 INPATIENT HOSPITALIZATION / OUTPATIENT CLINIC  
 
10.4 Precipitating factors for this hospitalization / outpatient clinic visit?  
 
No 0   Yes 1  
If Yes, specify:   
 
10.4.1 Acute coronary syndrome  Present 1 Absent 2 Not certain 3  
 
10.4.2 Non-Compliance (behavior, drugs)  Present 1 Absent 2 Not certain 3  
 
10.4.3 Atrial Fibrillation  Present 1 Absent 2 Not certain 3  
 
10.4.4 Ventricular Arrhythmia  Present 1 Absent 2 Not certain 3  
 
10.4.5 Infection  Present 1 Absent 2 Not certain 3  
 
10.4.6 Uncontrolled hypertension  Present 1 Absent 2 Not certain 3  
 
10.4.7 Brady arrhythmias  Present 1 Absent 2 Not certain 3  
 
10.4.8 Renal dysfunction  Present 1 Absent 2 Not certain 3  
 
10.4.9 Iatrogenic  Present 1 Absent 2 Not certain 3  
 
10.4.10 Other?  Present 1 Absent 2 Not certain 3  
             If Yes, specify     
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Supplementary table 2. Patients Characteristics according to Precipitating Factors 
 Global 
(N=845) 
ACS 
(N=68) 
Atrial fibrillation 
(N=353) 
Hypertension 
(N=67) 
Renal failure 
(N=100) 
Infection 
(N=64) 
Non-adherence 
(N=193) p-value 
Age, yrs 68.8 ± 12.0 69.1 ± 12.0 71.2 ± 10.6 68.5 ± 12.3 71.4 ± 13.0 68.7 ± 11.2 63.2 ± 12.5 <0.001 
Male, N (%) 595 (70.4 %) 46 (67.6 %) 250 (70.8 %) 40 (59.7 %) 73 (73.0 %) 39 (60.9 %) 147 (76.2 %) 0.07 
Body mass index, kg/m² 28.1 ± 5.3 27.5 ± 5.0 28.5 ± 5.5 28.0 ± 5.0 27.5 ± 4.9 26.8 ± 4.6 28.3 ± 5.6 0.21 
Medical history         
  Hypertension, N (%) 519 (61.4 %) 40 (58.8 %) 204 (57.8 %) 64 (95.5 %) 64 (64.0 %) 35 (54.7 %) 112 (58.0 %) <0.001 
  Diabetes mellitus, N (%) 288 (34.1 %) 27 (39.7 %) 100 (28.3 %) 23 (34.3 %) 44 (44.0 %) 22 (34.4 %) 72 (37.3 %) 0.04 
  Myocardial infarction, N (%) 293 (34.7 %) 53 (77.9 %) 85 (24.1 %) 16 (23.9 %) 46 (46.0 %) 26 (40.6 %) 67 (34.7 %) <0.001 
  Stroke, N (%) 94 (11.1 %) 5 (7.4 %) 46 (13.0 %) 2 (3.0 %) 12 (12.0 %) 12 (18.8 %) 17 (8.8 %) 0.04 
  PAD, N (%) 105 (12.4 %) 7 (10.3 %) 35 (9.9 %) 11 (16.4 %) 18 (18.0 %) 9 (14.1 %) 25 (13.0 %) 0.27 
  COPD, N (%) 144 (17.0 %) 10 (14.7 %) 54 (15.3 %) 9 (13.4 %) 18 (18.0 %) 24 (37.5 %) 29 (15.0 %) <0.001 
  Prior HF admission, N (%) 258 (30.5 %) 8 (11.8 %) 104 (29.5 %) 14 (20.9 %) 46 (46.0 %) 18 (28.1 %) 68 (35.2 %) <0.001 
Clinical profile         
  NYHA class ≥III, N (%) 551 (67.4 %) 32 (50.0 %) 234 (67.8 %) 36 (57.1 %) 75 (78.9 %) 51 (83.6 %) 123 (64.7 %) <0.001 
  Rales, N (%) 101 (20.4 %) 9 (20.5 %) 44 (21.9 %) 6 (13.0 %) 14 (25.9 %) 14 (26.9 %) 14 (14.1 %) 0.25 
  Juglar venous pressure, N (%) 183 (31.2 %) 9 (20.0 %) 78 (32.5 %) 10 (21.7 %) 29 (35.8 %) 21 (48.8 %) 36 (27.5 %) 0.03 
  Leg edema, N (%) 470 (66.0 %) 23 (46.0 %) 223 (73.1 %) 33 (60.0 %) 62 (68.9 %) 41 (71.9 %) 88 (56.8 %) <0.001 
  Systolic blood pressure, mmHg 125.8 ± 24.1 119.3 ± 22.3 123.7 ± 19.4 169.9 ± 25.8 118.9 ± 20.6 122.0 ± 22.8 121.4 ± 18.0 <0.001 
  Heart rate, bpm 82.6 ± 21.4 75.3 ± 15.5 89.0 ± 24.6 84.0 ± 21.3 73.9 ± 11.9 84.7 ± 22.0 76.7 ± 16.1 <0.001 
Hospitalized patients, N (%) 682 (80.7 %) 65 (95.6 %) 283 (80.2 %) 56 (83.6 %) 86 (86.0 %) 63 (98.4 %) 129 (66.8 %) <0.001 
Echocardiogram         
  LVEF, % 32.1 ± 11.2 31.8 ± 7.9 33.9 ± 12.1 34.9 ± 10.2 31.8 ± 11.0 31.3 ± 15.2 28.5 ± 8.3 <0.001 
  MR ≥moderate, N (%) 378 (46.8 %) 18 (27.7 %) 178 (52.0 %) 20 (30.3 %) 46 (50.0 %) 26 (43.3 %) 90 (49.2 %) <0.001 
Medication at baseline         
  ACEi or ARB, N (%) 609 (72.1 %) 55 (80.9 %) 252 (71.4 %) 49 (73.1 %) 58 (58.0 %) 42 (65.6 %) 153 (79.3 %) 0.002 
  %ACEi or ARB target dose 25.0 (0.0 - 50.0) 
25.0 
(12.5 - 50.0) 
25.0 
(0 - 50.0) 
50.0 
(0 - 100.0) 
15.5 
(0 - 50.0) 
25.0 
(0 - 50.0) 
25.0 
(12.5 - 50.0) 0.03 
  Beta-blocker, N (%) 697 (82.5 %) 60 (88.2 %) 290 (82.2 %) 52 (77.6 %) 79 (79.0 %) 46 (71.9 %) 170 (88.1 %) 0.03 
  %beta-blocker target dose 23.8 (6.2 - 37.5) 
25.0 
(12.5 - 37.5) 
25.0 
(6.2 - 50.0) 
15.6 
(4.2 - 50.0) 
12.5 
(4.2 - 50.0) 
12.5 
(0 - 48.8) 
12.5 
(6.2 - 25.0) 0.22 
  MRA, N (%) 441 (52.2 %) 29 (42.6 %) 185 (52.4 %) 27 (40.3 %) 39 (39.0 %) 35 (54.7 %) 126 (65.3 %) <0.001 
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  Loop diuretics dose, mg 40.0 (20.0 - 80.0) 
40.0 
(25.0 - 80.0) 
40.0 
(8.0 - 80.0) 
40.0 
(20.0 - 80.0) 
40.0 
(20.0 - 100.0) 
40.0 
(25.0 - 80.0) 
40.0 
(40.0 - 75.0) 0.02 
Medication at 3 months         
  ACEi/ARB ≥50% target dose 419 (49.6 %) 36 (52.9 %) 172 (48.7 %) 45 (67.2 %) 31 (31.0 %) 33 (51.6 %) 102 (52.8 %) <0.001 
  %ACEi/ARB target dose 37.5 (25.0 - 62.5) 
50.0 
(20.8 - 50.0) 
37.5 
(25.0 - 50.0) 
50.0 
(25.0 - 100.0) 
20.8 
(0 - 50.0) 
50.0 
(25.0 - 75.0) 
50.0 
(25.0 - 62.5) <0.001 
  Beta-blocker ≥50% target dose 280 (33.1 %) 16 (23.5 %) 134 (38.0 %) 26 (38.8 %) 36 (36.0 %) 19 (29.7 %) 49 (25.4 %) 0.02 
  %beta-blocker target dose 25.0 (12.5 - 50.0) 
25.0 
(14.6 - 47.5) 
25.0 
(12.5 - 50.0) 
25.0 
(12.5 - 50.0) 
25.0 
(8.3 - 50.0) 
25.0 
(6.2 - 50.0) 
25.0 
(12.5 - 50.0) 0.06 
Laboratory         
  Hemoglobin, g/dl 13.2 ± 1.9 12.7 ± 1.8 13.5 ± 1.9 13.6 ± 1.5 11.9 ± 2.1 12.4 ± 1.7 13.5 ± 1.9 <0.001 
  Blood urea nitrogen, mg/dl 39.7 ± 30.6 34.2 ± 33.1 36.2 ± 28.2 31.7 ± 26.5 61.5 ± 38.6 30.7 ± 19.7 41.8 ± 27.7 <0.001 
  eGFR, mL/min/1.73m² 62.5 ± 24.9 68.6 ± 20.0 65.8 ± 21.2 68.1 ± 26.5 30.5 ± 8.9 68.3 ± 36.0 67.7 ± 20.9 <0.001 
  Sodium, mmol/l 139.1 ± 3.9 138.8 ± 3.4 139.4 ± 3.8 140.3 ± 3.4 138.2 ± 4.3 137.2 ± 4.6 139.3 ± 3.9 <0.001 
  Potassium, mmol/l 4.3 ± 0.6 4.2 ± 0.5 4.2 ± 0.5 4.2 ± 0.6 4.4 ± 0.7 4.0 ± 0.6 4.4 ± 0.7 <0.001 
  NT-proBNP, pg/ml 4770 (585 - 8797) 
3408 
(1941 - 7764) 
3899 
(2559 - 7419) 
4988 
(3183 - 7921) 
7500 
(3723 - 15805) 
7255 
(3290 - 14111) 
5000 
(2090 - 8105) <0.001 
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Supplementary table 3. Cox Proportional Hazard Models of the Heart Failure Etiologies for the Primary Outcome in Ambulant and Hospitalized 
Patients 
 
Ambulant Patients Hospitalized Patients P-value for 
interaction with 
ambulatory/ 
hospitalization N Event (%) HR (95% CI) P-value N Event (%) HR (95% CI) P-value 
Etiologies          
  Dilated cardiomyopathy 197 17.3 (reference)  366 35.8 (reference)  
0.51 
  Ischemic HF 397 34.3 1.46 (0.99 - 2.14) 0.056 705 52.1 1.32 (1.08 - 1.61) 0.007 
  Hypertensive HF 81 40.7 1.50 (0.92 - 2.44) 0.11 156 42.9 1.17 (0.87 - 1.57) 0.31 
  Valvular HF 36 41.7 1.48 (0.80 - 2.74) 0.21 148 48 1.14 (0.85 - 1.52) 0.39 
  Other/Unknown 100 26 1.26 (0.75 - 2.10) 0.38 279 39.4 1.11 (0.86 - 1.43) 0.42 
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Supplementary table 4. Cox Proportional Hazard Models of the Heart Failure Etiologies for the Primary Outcome in Patients with Reduced Ejection 
Fraction 
 N Event (%) HR (95% CI) P-value 
Etiologies     
Dilated cardiomyopathy 517 28.8 (reference)  
Ischemic HF 915 43.6 1.36 (1.13 - 1.65) 0.001 
Hypertensive HF 170 40.0 1.24 (0.93 - 1.66) 0.14 
Valvular HF 116 37.9 0.99 (0.70 - 1.38) 0.94 
Other/Unknown 255 32.5 1.19 (0.91 - 1.56) 0.20 
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Supplementary figure 1. Unadjusted Survival Curves for the Primary Outcome according to the Heart Failure Etiologies and Precipitating Factors 
(Overall Term Follow-up)
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Supplementary figure 2. Unadjusted Survival Curves for the Primary Outcome according to the Heart Failure Etiologies and Precipitating Factors 
 
 
